FULL REPORT [US$ 18 000 (eighteen thousand US Dollars)]

INTRODUCTION [US$ 0]

• Table 1-1 HEALTH CARE INDUSTRY TERMS USED IN THIS REPORT

OVERVIEW [US$ 550]

• Table 2-1 PREFERRED PROVIDER ORGANIZATIONS IN THE UNITED STATES BY TYPE OF OWNER, 2002
• Table 2-3 SUMMARY OF LEADING U.S. PHARMACY BENEFIT MANAGERS
• Figure 2-1 PERCENTAGE OF PARTICIPANTS BY TYPE OF HEALTH CARE PLAN
• Figure 2-2 SHARE OF PRESCRIPTION DRUG COVERAGE PAYORS IN 2003
• Figure 2-3 NUMBER OF PARTICIPANTS BY TYPE OF HEALTH CARE PLAN
• Figure 2-4 HMO PRESCRIPTIONS AND DRUG COSTS, 2001 AND 2002
• Table 2-4 POLICY ON USE OF OTC DRUGS IN MEDICAID MANAGED CARE PROGRAMS IN SELECT STATES
• Table 2-2 ENROLLMENT OF LEADING U.S. MANAGED CARE ORGANIZATIONS, 2000 TO 2002

RX-TO-OTC SWITCHES [US$ 2 000]

• Table 3 1 MAJOR RX-TO-OTC SWITCHES, 1976 TO 2002
• Table 3-2 PRE- AND POST-SWITCH SALES OF SELECT RX-TO-OTC SWITCHES
• Figure 3-1 PERCENTAGE SHARE OF OTC VERSUS PRESCRIPTION MEDICATIONS IN ALLERGY-DRUG-PURCHASING HOUSEHOLDS, 2002 TO 2003
• Table 3-3 ISSUES AFFECTING RX-TO-OTC SWITCH POSITIONS OF KEY HEALTH CARE SECTORS
• Table 3-4 LIKELIHOOD OF DRUG CLASSES MAKING THE RX-TO-OTC SWITCH
• Table 3-5 MCO STRATEGIES TO PROMOTE USE OF PRILOSEC OTC
• Table 3-6 MCO STRATEGIES TO PROMOTE USE OF CLARITIN/LORATADINE
• Table 3-7 PBM STRATEGIES TO PROMOTE USE OF PRILOSEC OTC
• Table 3-8 PBM STRATEGIES TO PROMOTE USE OF CLARITIN/LORATADINE

MCO/PBM POSITIONS ON FORCED SWITCHES [US$ 4 500]

• Table 4-1 CHRONOLOGY OF EVENTS IN PETITION TO FORCE LORATADINE TO SWITCH TO OTC STATUS
• Table 4-2 CHRONOLOGY OF EVENTS IN PRILOSEC Rx-TO-OTC SWITCH
• Table 4-3 ATTRACTIVENESS TO MCOs OF DRUG CLASSES FOR RX-TO-OTC SWITCH
• Table 4-4 RELATIVE COSTS TO MCOs OF COVERING PRESCRIPTION DRUG CLASSES IN 2002
• Figure 4-1 PERCENTAGE OF MCO SPENDING BY DRUG CATEGORY, 2002
• Table 4-7 MCOs LIKELY TO COVER FUTURE SWITCHED DRUGS
• Table 4-8 PBMs LIKELY TO RECOMMEND COVERAGE OF FUTURE SWITCHED DRUGS
• Table 4-5 POSITIONS OF TOP MCOs ON FORCED SWITCHES
• Table 4-6 POSITIONS OF TOP PBMs ON FORCED SWITCHES

COVERAGE OF OTC DRUGS [US$ 4 500]

• Figure 5-1 TYPE OF FORMULARY DESIGN USED BY HEALTH CARE PLANS, 2003
• Table 5-2 RETAIL PRICES OF SOME POPULAR OTC PRODUCTS
• Table 5-3 OTC COVERAGE FOR SELF-INSURED EMPLOYERS, 2002
• Figure 5-2 PERCENTAGE OF HMOs COVERING OTC DRUGS BY MODEL TYPE, 2000 TO 2002
• Table 5-5 MCOs THAT SPECIFICALLY EXCLUDE ALL OTCs FROM COVERAGE
• Table 5-6 PBMs THAT RECOMMEND OTC COVERAGE
• Table 5-1 PERCENTAGE OF HMO MEMBERS AND PRESCRIPTIONS DISPENSED, BY CO PAY TIER SYSTEM
• Table 5-4 MCOs THAT COVER OTC DRUGS

PROMOTIONAL AND COUPONING PROGRAMS [US$ 4 500]

• Table 6-1 COMMON PROGRAMS TO PROMOTE OTC DRUGS
• Table 6-2 FREESTANDING MCO PROGRAMS TO PROMOTE OTC DRUGS
• Table 6-3 MCOs THAT DO NOT PROMOTE OTC DRUGS
• Table 6-4 MCO PROMOTIONAL PROGRAMS FOR OTC DRUGS
• Table 6-5 PBM PROMOTIONAL PROGRAMS FOR OTC DRUGS
• Table 6-6 COMMON PROBLEMS IN MCO/PBM COLLABORATIONS WITH OTC DRUG COMPANIES
• Figure 6-1 WELLPOINT PATIENTS WHO FILLED NONSEDATING ANTIHISTAMINE PRESCRIPTIONS, 2002 AND 2003
• Table 6-7 RECENT NOTABLE PATENT EXPIRATIONS
• Table 6-8 TOTAL OTC PRODUCT SALES OF LEADING NONPRESCRIPTION DRUG COMPANIES, 2002 AND 2003
• Figure 6-2 OTC SALES COMPARED WITH MCO PROGRAM STRENGTH FOR LEADING PHARMACEUTICAL COMPANIES, 2003
• Table 6-9 LEADING OTC PRODUCTS PROMOTED TO MCOs BY PRODUCT CLASS
• Table 6-10 LEADING PRODUCTS OF OTC DRUG COMPANIES
• Table 6-11 OTC PROMOTIONAL CAPABILITIES IN THE NONPRESCRIPTION DRUG INDUSTRY

PARTNERSHIP OPPORTUNITIES FOR MCOs/PBMs AND OTC COMPANIES
[US$ 4 500]

• Table 7-1 OPPORTUNITIES FOR OTC PROMOTIONAL STRATEGIES WITH MCOs/PBMs
• Table 7-2 AFFECT OF KEY TRENDS ON OTC COVERAGE AND OTC PROMOTION BY MCOs/PBMs
• Table 7-3 POTENTIAL HIGH-PROFILE RX-TO-OTC SWITCHES
• Table 7-4 SIGNIFICANT RECENT AND PENDING PHARMACEUTICAL MERGERS
• Table 7-5 KEY OPPORTUNITIES FOR OTC PROMOTIONS WITH MCOs/PBMs

FORECASTS AND ASSESSMENTS [US$ 4 500]

STEP 2 of 3

All fields in *BOLD are required.

STEP 3 of 3

*Please view our terms and conditions, and check this box to indicate your acceptance of these terms and conditions.

Thank you for your interest in subscribing to our syndicated reports. To complete this process, please click on the button below and a member of our global sales team will contact you shortly to confirm the final price and complete the transaction. Upon acceptance of your order, we will deliver the files in PDF format via email.